Skip to main content

JHOP - August 2022 Vol 12, No 4

ASCO Highlights
Editorial
Case Reports
Original Research
Practical Issues in Pharmacy Management
FDA Updates
ASCO Highlights
Meeting Highlights Online Only
ASCO Highlights
PD-1 Inhibition with Dostarlimab Led to Remission in All Patients with Mismatch Repair-Deficient Rectal Cancer
Read More
Meeting Highlights Online Only
ASCO Highlights
Black Patients with Cancer and COVID-19 More Likely Than White Patients to Have Therapy Disruptions
Read More
Meeting Highlights Online Only
ASCO Highlights
Trastuzumab Deruxtecan a New Standard for Patients with HER2-Low Metastatic Breast Cancer
Read More
Meeting Highlights Online Only
ASCO Highlights
Patients Aged ≥55 Years with Luminal A Breast Cancer Can Safely Avoid Radiation
Read More
Meeting Highlights Online Only
ASCO Highlights
ASCO Highlights Innovation as Key to Equitable Cancer Care
Read More
Editorial
Editorial
Optimal Sequencing of Cancer Treatments an Increasingly Important Question
Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Read More
Case Reports
Case Reports, Lung Cancer, Tyrosine Kinase Inhibitor
Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer
Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD
Read More
Original Research
Original Research, Prostate Cancer, Genitourinary Cancers, Targeted Therapies
Comparing the Impact of Abiraterone and Enzalutamide Sequencing on Progression-Free Survival in Veterans with Metastatic Castration-Resistant Prostate Cancer
Nicholas J. Newman, PharmD; Sara E. Gordon, PharmD, BCOP; Charles J. Nock, MD; Christopher J. Burant, PhD; Candice M. Wenzell, PharmD, BCOP
Read More
Original Research, Adverse Events, Oral Therapy, Tyrosine Kinase Inhibitor
The Link Between Hypoalbuminemia and Oral Tyrosine Kinase Inhibitor Adverse Events in Adults with Malignant Solid Tumors
Jessica Marini, PharmD, BCOP; Bailey Bass Hammond, PharmD; Jacob Rennebaum, PharmD; Erin Weeda, PharmD, BCPS; Jagoda Misniakiewicz, PharmD; Amy Sion, PharmD, BCOP
Read More
Original Research, Adverse Events
Safety and Efficacy of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients with Cancer and Baseline Renal Dysfunction
Emily H. Hsu, PharmD, and Ryan Beechinor, PharmD, BCPS, BCOP
Read More
Practical Issues in Pharmacy Management
Practical Issues in Pharmacy Management
Sterility of Single-Use Vials When Using a Closed-System Transfer Device
Joan Antoni Schoenenberger-Arnaiz, PharmD, PhD; Maria Nevot-Blanc, PharmD; Merce Garcia-Gonzalez, PharmD; Mireia Martinez-Sogues, PharmD; Aida Moroba-Estor; Laura Rumi-Carrera, PharmD; Jason Battle, BS
Read More
FDA Updates
FDA Updates
Xalkori Now FDA Approved for the Treatment of ALK-Positive Inflammatory Myofibroblastic Tumor
Read More
FDA Updates
Breyanzi Now FDA Approved for Second-Line Treatment of Large B-Cell Lymphoma
Read More
FDA Updates
Tafinlar plus Mekinist First Tumor Agnostic Therapy Approved for Any Unresectable or Metastatic Solid Tumors with BRAF Mutation
Read More
Online Only
FDA Updates
FDA Issues New Warning for Copiktra About Increased Risks for Serious Side Effects and Mortality
Read More
Online Only
FDA Updates, Monoclonal Antibodies, Bispecific Antibodies
Talquetamab, First-in-Class Bispecific Monoclonal Antibody, Granted Breakthrough Therapy by the FDA for Relapsed or Refractory Multiple Myeloma
Read More